{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:21:01Z","timestamp":1778948461461,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T00:00:00Z","timestamp":1423267200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12911-014-0128-0","type":"journal-article","created":{"date-parts":[[2015,2,6]],"date-time":"2015-02-06T02:40:57Z","timestamp":1423190457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children"],"prefix":"10.1186","volume":"15","author":[{"given":"Anna-Karin","family":"Hamberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Hellman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonny","family":"Dahlberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E Niclas","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Wadelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,7]]},"reference":[{"key":"128_CR1","doi-asserted-by":"publisher","first-page":"e737S","DOI":"10.1378\/chest.11-2308","volume":"141","author":"P Monagle","year":"2012","unstructured":"Monagle P, Chan AKC, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Gottl U, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e737S\u2013801S.","journal-title":"Chest"},{"key":"128_CR2","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1182\/blood-2014-04-568436","volume":"124","author":"R Daneshjou","year":"2014","unstructured":"Daneshjou R, Gamazon ER, Burkley B, Cavallari LH, Johnson JA, Klein TE, et al. Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood. 2014;124:2298\u2013305.","journal-title":"Blood"},{"key":"128_CR3","unstructured":"The Swedish Prescribed Drug register, The National Board of Health and Welfare. http:\/\/www.socialstyrelsen.se\/statistik\/statistikdatabas\/lakemedel (accessed on October 16, 2014)"},{"key":"128_CR4","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/blood-2008-04-149070","volume":"113","author":"M Wadelius","year":"2009","unstructured":"Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJR, Bumpstead S, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009;113:784\u201392.","journal-title":"Blood"},{"key":"128_CR5","doi-asserted-by":"publisher","first-page":"e27808","DOI":"10.1371\/journal.pone.0027808","volume":"6","author":"IY Gong","year":"2011","unstructured":"Gong IY, Schwarz UI, Crown N, Dresser GK, Lazo-Langner A, Zou G, et al. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS One. 2011;6:e27808.","journal-title":"PLoS One"},{"key":"128_CR6","doi-asserted-by":"publisher","first-page":"e44064","DOI":"10.1371\/journal.pone.0044064","volume":"7","author":"AL Jorgensen","year":"2012","unstructured":"Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One. 2012;7:e44064.","journal-title":"PLoS One"},{"key":"128_CR7","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1378\/chest.126.6.1938","volume":"126","author":"MW Reynolds","year":"2004","unstructured":"Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004;126:1938\u201345.","journal-title":"Chest"},{"key":"128_CR8","first-page":"386","volume":"12","author":"M Zareh","year":"2011","unstructured":"Zareh M, Davis A, Henderson S. Reversal of warfarin-induced hemorrhage in the emergency department. West JEM. 2011;12:386\u201392.","journal-title":"West JEM"},{"issue":"9","key":"128_CR9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.18553\/jmcp.2011.17.9.672","volume":"17","author":"SR Ghate","year":"2011","unstructured":"Ghate SR, Biskupiak J, Ye X, Kwong WJ, Brixner DI. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm. 2011;17(9):672\u201384.","journal-title":"J Manag Care Pharm"},{"key":"128_CR10","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa0809329","volume":"360","author":"TE Klein","year":"2009","unstructured":"International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753\u201364.","journal-title":"N Engl J Med"},{"key":"128_CR11","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1182\/blood-2010-05-283861","volume":"116","author":"U Nowak-Gottl","year":"2010","unstructured":"Nowak-Gottl U, Dietrich K, Schaffranek D, Eldin NS, Yasui Y, Geisen C, et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood. 2010;116:6101\u20135.","journal-title":"Blood"},{"key":"128_CR12","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1182\/blood-2011-08-372722","volume":"119","author":"TT Biss","year":"2012","unstructured":"Biss TT, Avery PJ, Brandao LR, Chalmers EA, Williams MD, Grainger JD, et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood. 2012;119:868\u201373.","journal-title":"Blood"},{"key":"128_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1182\/blood-2011-07-365502","volume":"119","author":"C Moreau","year":"2012","unstructured":"Moreau C, Bajolle F, Siguret V, Lasne D, Golmard JL, Elie C, et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood. 2012;119:861\u20137.","journal-title":"Blood"},{"key":"128_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/sj.bmt.1703229","volume":"28","author":"M Sandstr\u00f6m","year":"2001","unstructured":"Sandstr\u00f6m M, Karlsson MO, Ljungman P, Hassan Z, Jonsson EN, Nilsson C, et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Trans. 2001;28:657\u201364.","journal-title":"Bone Marrow Trans"},{"key":"128_CR15","volume-title":"Dose adaptation based on pharmacometric models","author":"J Wallin","year":"2009","unstructured":"Wallin J. Dose adaptation based on pharmacometric models. Uppsala: Acta Universitatis Upsaliensis; 2009."},{"key":"128_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/FTD.0b013e3181aab02b","volume":"31","author":"JE Wallin","year":"2009","unstructured":"Wallin JE, Friberg LE, Fasth A, Staatz CE. Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. Ther Drug Mon. 2009;31:457\u201366.","journal-title":"Ther Drug Mon"},{"key":"128_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/FTD.0b013e318203b41e","volume":"33","author":"E Dombrowsky","year":"2011","unstructured":"Dombrowsky E, Jayaraman B, Narayan M, Barrett JS. Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Mon. 2011;33:99\u2013107.","journal-title":"Ther Drug Mon"},{"key":"128_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cmpb.2008.10.011","volume":"93","author":"JE Wallin","year":"2009","unstructured":"Wallin JE, Friberg LE, Karlsson MO. A tool for neutrophil guided dose adaptation in chemotherapy. Comput Methods Programs Biomed. 2009;93:283\u201391.","journal-title":"Comput Methods Programs Biomed"},{"key":"128_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40262-012-0017-6","volume":"52","author":"DFB Wright","year":"2013","unstructured":"Wright DFB, Duffull SB. A Bayesian dose-individualization method for warfarin. Clin Pharmacokinet. 2013;52:59\u201368.","journal-title":"Clin Pharmacokinet"},{"key":"128_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/sj.clpt.6100084","volume":"81","author":"A-K Hamberg","year":"2007","unstructured":"Hamberg A-K, Dahl ML, Barban M, Scordo MG, Wadelius M, Pengo V, et al. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther. 2007;81:529\u201338.","journal-title":"Clin Pharmacol Ther"},{"key":"128_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/clpt.2010.37","volume":"87","author":"A-K Hamberg","year":"2010","unstructured":"Hamberg A-K, Wadelius M, Lindh JD, Dahl ML, Padrini R, Deloukas P, et al. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther. 2010;87:727\u201334.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"128_CR22","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00228-012-1466-4","volume":"69","author":"A-K Hamberg","year":"2013","unstructured":"Hamberg A-K, Friberg LE, Hans\u00e9us K, Ekman-Joelsson B-M, Sunneg\u00e5rdh J, Jonzon A, et al. Warfarin dose prediction in children using pharmacometric bridging\u2014comparison with published pharmacogenetic dosing algorithms. Eur J Clin Pharmacol. 2013;69(6):1275\u201383.","journal-title":"Eur J Clin Pharmacol"},{"key":"128_CR23","volume-title":"NONMEM users guide. Introduction to NONMEM 7.2.0","author":"R Bauer","year":"2011","unstructured":"Bauer R. NONMEM users guide. Introduction to NONMEM 7.2.0. Ellicott City, Maryland: ICON Development Solutions; 2011."},{"key":"128_CR24","unstructured":"Netbeans.org [http:\/\/www.netbeans.org]"},{"key":"128_CR25","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2217\/pgs.10.49","volume":"11","author":"SA Scott","year":"2010","unstructured":"Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics. 2010;11:781\u201391.","journal-title":"Pharmacogenomics"},{"key":"128_CR26","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1182\/blood-2009-12-255992","volume":"115","author":"NA Limdi","year":"2010","unstructured":"Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MTM, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010;115:3827\u201334.","journal-title":"Blood"},{"key":"128_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2217\/pgs.14.8","volume":"15","author":"A-K Hamberg","year":"2014","unstructured":"Hamberg A-K, Wadelius M. Pharmacogenetics-based warfarin dosing in children. Pharmacogenomics. 2014;15:361\u201374.","journal-title":"Pharmacogenomics"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12911-014-0128-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-014-0128-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-014-0128-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-014-0128-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T07:52:43Z","timestamp":1630569163000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-014-0128-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["128"],"URL":"https:\/\/doi.org\/10.1186\/s12911-014-0128-0","relation":{},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,7]]},"assertion":[{"value":"13 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"7"}}